Bitget App
Trade smarter
Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5%

Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5%

Bitget-RWA2025/11/11 00:06
By:Bitget-RWA

- Australia-based Propanc Biopharma secured up to $100M from Hexstone Capital to build a crypto treasury and advance its cancer therapy PRP, targeting first-in-human trials by 2026. - The funding strategy reflects a growing trend in biotech to leverage crypto assets for non-dilutive capital, with Hexstone’s portfolio including Bitcoin , Ether , and Solana . - CEO James Nathanielsz called the move "transformative," aiming to diversify Propanc’s assets while tying capital to clinical milestones, though share

Headquartered in Australia,

has obtained a funding commitment of up to $100 million from Hexstone Capital, a family office specializing in cryptocurrency, to build a digital asset treasury and further its cancer treatment research . The agreement starts with an initial $1 million investment via convertible preferred shares, followed by the possibility of an additional $99 million over the coming year . The capital will be used to establish a crypto treasury and speed up the development of its flagship therapy, PRP, which is slated to begin its first human trials in the latter half of 2026 . CEO James Nathanielsz called this a "transformative period" for the company, highlighting the opportunity to bolster Propanc’s financial position and broaden its asset portfolio .

This financing approach mirrors a rising trend among biotech companies turning to crypto treasuries as traditional capital markets become more challenging. Firms such as Sonnet BioTherapeutics and Sharps Technology have also embraced digital asset strategies to attract investors and diversify their funding streams

. Industry experts note that this movement has since 2023, as biotech companies look for non-dilutive funding in the $2.5 trillion crypto sector . However, Propanc’s strategy has received a mixed response from the market.
Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5% image 0
Shares of (PPCB) dropped by 10.5% on Nasdaq after the news, adding to a 46.7% decrease over the previous month . This decline highlights investor caution regarding the integration of crypto assets in established industries, especially given recent fluctuations in and values .

Hexstone Capital, which has supported other crypto treasury projects, has not specified which digital assets Propanc intends to purchase. Still, its holdings include Bitcoin (BTC), Ether (ETH),

(SOL), and Injective (INJ), suggesting a focus on high-growth cryptocurrencies . Propanc’s CEO pointed out that the company’s proenzyme therapy is designed to treat both solid tumors and chronic illnesses, utilizing a distinct mechanism of action . The company’s funding model aims to address common biotech financing hurdles by linking capital releases to clinical progress, ensuring that resources are directed toward research and development rather than speculation .

The broader landscape for crypto treasury firms has encountered difficulties, with companies like Strategy and Metaplanet seeing notable drops in market capitalization

. Despite these obstacles, Propanc’s phased funding approach—allocating capital incrementally to clinical trials and treasury growth—aims to balance innovation with financial discipline . Analysts observe that while crypto-based fundraising can be 20-30% faster than conventional methods , it also brings regulatory and market volatility risks. The SEC’s increased attention to crypto reporting adds complexity, requiring clear and accurate disclosures to protect investors .

Propanc’s combined focus on cancer research and digital assets places it at the crossroads of two rapidly expanding industries. Preclinical studies of PRP have demonstrated a 70% reduction in tumor size in animal tests

, offering new hope for patients with advanced cancers. As the company moves toward human trials in 2026, investors will be monitoring both clinical progress and market conditions to assess the sustainability of its dual-pronged strategy .

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

CoreWeave's AI Surge Reaches $55B in Orders, Yet $12B in Capital Spending and Debt Raise Concerns Over Profitability

- CoreWeave reported $1.36B Q3 revenue (134% YoY) and $55.6B backlog, driven by AI cloud demand. - Stock fell 3.68% despite $12B 2025 CapEx, $110M net loss, and CEO selling $5.7M shares. - Partnership with CrowdStrike aims to secure AI infrastructure, but investors question profitability. - 2026 CapEx forecast at $28B raises concerns about converting $55.6B backlog into cash flow.

Bitget-RWA2025/11/11 01:46
CoreWeave's AI Surge Reaches $55B in Orders, Yet $12B in Capital Spending and Debt Raise Concerns Over Profitability